Dexasone
Early T Cell Progenitor Acute Lymphoblastic Leukemia
Explore 3 assets in Early T Cell Progenitor Acute Lymphoblastic Leukemia →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Nanfang Hospital, Southern Medical University
Modality
Small molecule
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03553238CT.gov Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | — | Unknown | — | — | — |
NCT03564704CT.gov Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Early T Cell Progenitor Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Nanfang Hospital, Southern Medical University | P2/3 | B · 57 |
| Cytarabine | yuejun Liu | P2/3 | BB |
| Idarubicin | Nanfang Hospital, Southern Medical University | P2/3 | B |
| Mercaptopurine Anhydrous | Nanfang Hospital, Southern Medical University | P2/3 | B |
| (+)-Vincristine | Nanfang Hospital, Southern Medical University | P2/3 | B |
| Cyclophosphamide | Nanfang Hospital, Southern Medical University | P2/3 | B |
| Etoposide | Nanfang Hospital, Southern Medical University | P2/3 | B |
| Adriamycin | Nanfang Hospital, Southern Medical University | P2/3 | B |
| Tucidinostat | Nanfang Hospital, Southern Medical University | P2/3 | B |
+4 more in the Early T Cell Progenitor Acute Lymphoblastic Leukemia cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in Early T Cell Progenitor Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-early-t-cell-progenitor-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →